1.
Analyst
; 146(4): 1157-1162, 2021 Feb 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33426547
RESUMO
Adaptive resistance is a major limitation in the use of targeted therapies for cancer. Using real time biomass tracking, we demonstrate the isolation and identification of rare (1% fraction) diffuse large B cell lymphoma cells resistant to the PI3K inhibitor idelalisib, from an otherwise sensitive population. This technique allows direct study of these rare, drug tolerant cells.